Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease
The therapeutic rationale for using GLP-1 receptor agonists in these conditions revolves around their ability to increase insulin secretion, decrease glucagon secretion, slow gastric emptying, and reduce appetite and food intake, all of which contribute to improved glycemic control and weight loss
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
Wang HL, Zhang J, Li YP, Dong L, Chen YZ
Skin Detoxification: Eliminates free radicals, lowers liver toxicity, and enhances the health of hair and nails
9 ) shows that the presence of bafilomycin A1 (0.25 nM or 1 nM) did not have a significant effect on tamoxifen induced collateral sensitivity in CHO R C5 cells